Phase 1 Hypertension Trial, Recruiting NCT07282171 Sponsor: Comanche Biopharma Condition: Hypertension
Back to Hypertension

Phase 1 Hypertension Trial, Recruiting

NCT07282171
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are pregnant and currently in hospital with a condition called preeclampsia (high blood pressure after 20 weeks of pregnancy, along with protein in the urine or signs that organs such as the kidneys or liver are not working normally)
  • People who are expected to stay in hospital until they give birth
  • People who are between 18 and 45 years old
  • People who are between 26 weeks and 35 weeks and 6 days into their pregnancy at the start of the trial
  • People whose condition is considered stable enough that delivery is not expected to be needed for at least 72 hours after receiving the study treatment
  • People who are carrying one baby (not twins or more)
  • People who have given written agreement to take part in the study

Who may not be able to join:

  • People with certain placenta problems, such as the placenta covering the birth canal, the placenta separating early, the placenta growing into the uterine wall, or unexplained ongoing vaginal bleeding
  • People whose baby is not growing as expected, or where the baby has a known major chromosomal or genetic condition
  • People whose condition requires immediate delivery — for example, very high blood pressure that cannot be controlled, seizures, signs the baby is not coping, or fluid in the lungs
  • People with an active infection that may affect the placenta
  • People with certain serious health conditions, such as HELLP syndrome, advanced kidney disease, severe heart disease, an uncontrolled neurological condition, or lupus affecting the kidneys or brain
  • People who have taken part in another clinical drug trial within the 30 days before joining this study
  • People whose treating doctor considers there to be any other reason that taking part could pose a risk to the mother or baby

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 248-520-7361

Australian sites

The Royal Women's Hospital, Parkville, Victoria
Monash University, Melbourne,
0456 409 087
Royal Melbourne, Melbourne,
(03) 8345 3703

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Comanche Biopharma
Registry
ClinicalTrials.gov
Start date
26 February 2025
Est. completion
31 March 2027

Where this trial is recruiting

🇦🇺 Australia

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Incidence of treatment emergent events and adverse events of special interest when CBP-4888 is administered to pregnant participants; Determine recommended phase 2 dose

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov